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EDITORIAL Open Access
Get together to increase awareness in
bronchiectasis: a report of the 2nd World
Bronchiectasis Conference
Stefano Aliberti1* and James D. Chalmers2
From 2nd World Bronchiectasis Conference
Milan, Italy. 06-08 July 2017
Bronchiectasis is a chronic respiratory disease character-
ized by a permanent dilation of the bronchi associated
with cough, daily sputum production and recurrent
episodes of respiratory infections [1]. Bronchiectasis
pathophysiology starts with a structural airway damage
leading to an impaired mucociliary clearance, subsequent
chronic bacterial infection and neutrophilic inflammation,
which perpetuates this vicious cycle [1]. For a long period
of time, bronchiectasis has been recognized as an isolated
radiological finding, while now we understand it as
chronic and debilitating disease which requires specific
management to improve patients’ outcomes.
A renewed interest in bronchiectasis has characterized
the field of respiratory medicine over the past few years.
When bronchiectasis has been the main theme of scien-
tific sessions at national or international meetings,
rooms are packed with colleagues sharing their intellec-
tual interest in this disease. The multidisciplinary ap-
proach which characterizes the management of
bronchiectasis naturally predisposes physicians to share
their experiences and work together to define common
pathways to optimize patients’ care [1, 2]. This is some-
thing that rarely happens in our field and is the reason
why we have seen such a substantial increase in the
awareness of bronchiectasis which has, in turn, led to a
better knowledge on different aspects of this disease.
Bronchiectasis is no more a neglected disease, nor
even less a rare one. Recent data suggest a prevalence
up to 566/100,000 subjects in the general population
with an increase of approximately 40% in the past
decade [3]. Bronchiectasis significantly impacts health-
care systems worldwide with an annual exacerbation
frequency up to 3 per patient per year and has a
clear attributable mortality [4]. However, real-life data
suggest that, to date, quality of bronchiectasis care re-
mains poor [5]. A new and emerging interest has
been promoted on this condition as demonstrated by
an increase in research activity and the development
of international registries over the past few years [6].
New areas of the disease management have been re-
cently considered and different research and clinical
gaps have been identified [7].
This special issue of Multidisciplinary Respiratory
Medicine is following up the largest meeting ever held
exclusively focused on bronchiectasis, the 2nd Word
Bronchiectasis Conference (WBC, Milan, Italy, July 2017;
www.world-bronchiectasis-conference.org). This congress,
like the previous one held in Hannover, Germany, in 2016
(world-bronchiectasis-conference.com), represents the
clear evidence of the emergence of bronchiectasis as a key
clinical entity. Meetings like the WBCs offer the possibility
for different healthcare professionals working on bronchi-
ectasis to get together from different continents and
actively discuss fundamental aspects of the disease man-
agement. These meetings also offer unique opportunities
to strengthen collaborations with patients and regulatory
agencies, and for young investigators to publish their work
with an exceptional international visibility [8]. Important
steps towards a better understanding of bronchiectasis
have been taken during both WBCs. In Hannover, an
international group of investigators developed a consensus
definition of exacerbation for clinical trials involving
patients with bronchiectasis [9]. In the same line, a discus-
sion started at the 2nd WBC in Milan between bronchiec-
tasis patients and healthcare professionals on the risk of
cross-infection which ended up with the first position
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statement from the European Bronchiectasis Network,
EMBARC/ELF patient advisory group and European
Reference Network Bronchiectasis Network on this
topic [10].
Bronchiectasis is a heterogeneous respiratory disorder
and represents the final pathway of several infectious,
genetic, immunologic or allergic diseases [11, 12]. An
accurate and prompt identification of the underlying
cause is a key recommendation of several international
guidelines, including rare diseases such as cystic fibrosis
(CF) and primary ciliary dyskinesia (PCD) [13, 14]. The
diagnosis of PCD and CF has relevant clinical, socio-
economic and psychological implications, which affect
patients’ life, including the possibility to have a spe-
cific and multidisciplinary team approach in referral
centres, as well as a genetic and fertility counselling
and special legal aspects in some countries. Both
PCD and CF have been hot topics discussed during
the 2nd WBC and are arguments of three different
papers published in the present issue [15–17]. The
papers by Gramegna and Contarini review current lit-
erature on PCD and CF and offer interesting insights
on why, when and how to investigate both conditions
in bronchiectasis, while Robinson and co-workers
summarize structural findings of PCD and highlight
the radiological differences between PCD and other
causes of bronchiectasis [15–17]. An entire session of
the 2nd WBC has been dedicated to non-tuberculous
mycobacteria (NTM) as one of the most difficult-
to-treat pathogens in bronchiectasis [18]. Several open
questions exist on NTM from the microbiological
diagnosis to the identification of NTM lung disease in
the context of a chronic respiratory disease such as
bronchiectasis [19]. Real life data coming from inter-
national registries are valuable to understand current
practices and design translational research [6]. This is
the case of the Italian Registry of Pulmonary NTM
(IRENE; www.registroirene.it) whose protocol has
been reported in the present issue of the journal [20].
New diagnostic techniques have been presented and
discussed at the conference such as shotgun metage-
nomic sequencing which provides an alternative
approach that allows the microbial composition of
clinical samples to be described in detail, including
the prevalence of resistance genes and virulence traits.
Rogers and co-workers described a novel, cost-effect-
ive strategy for screening patient cohorts for changes
in resistance gene prevalence and identified
population-level changes in the relative abundance of
specific macrolide resistance genes [21]. This is just
one of the examples of how new technologies are ad-
vancing our understanding of bronchiectasis and how
future multi-omics approaches performed across large
multicentre studies might help us in interpreting the
heterogeneity of this disease [22]. The 2nd WBC has
been one of the most productive meeting exclusively
focused on bronchiectasis and helped to pave the way
towards an increase in bronchiectasis knowledge
which will bring us to Washington DC, USA, where
the 3rd WBC will be held next July.
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